Anti-IL-4/IL-13 Biologics
作者： Girolamo Pelaia , Alessandro Vatrella , Rosario Maselli , Girolamo Pelaia , Alessandro Vatrella
DOI: 10.1007/978-3-319-46007-9_6
关键词:
摘要: The recent advances in our understanding of asthma pathobiology can have relevant implications both present and future therapeutic approaches. Within this context, the current more detailed knowledge key cellular molecular mechanisms underlying is unravelling potential targets such as IL-4 IL-13 for development implementation new biological therapies [1].
springer.com
unisa.it参考文章(50)
Garry Michael Walsh, Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD. Current opinion in investigational drugs. ,vol. 11, pp. 1305- 1312 ,(2010)
Ryan P. Andrews, Lillian Rosa Rosa, Michael O. Daines, Gurjit K. Khurana Hershey, Reconstitution of a Functional Human Type II IL-4/IL-13 Receptor in Mouse B Cells: Demonstration of Species Specificity Journal of Immunology. ,vol. 166, pp. 1716- 1722 ,(2001) , 10.4049/JIMMUNOL.166.3.1716
Christopher E Brightling, Pascal Chanez, Richard Leigh, Paul M O'Byrne, Stephanie Korn, Dewei She, Richard D May, Katie Streicher, Koustubh Ranade, Edward Piper, Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial The Lancet Respiratory Medicine. ,vol. 3, pp. 692- 701 ,(2015) , 10.1016/S2213-2600(15)00197-6
Peter Hodsman, Claire Ashman, Anthony Cahn, Erika De Boever, Nicholas Locantore, Adrian Serone, Isabelle Pouliquen, A phase 1, randomized, placebo‐controlled, dose‐escalation study of an anti‐IL‐13 monoclonal antibody in healthy subjects and mild asthmatics British Journal of Clinical Pharmacology. ,vol. 75, pp. 118- 128 ,(2013) , 10.1111/J.1365-2125.2012.04334.X
Tao Zheng, Wei Liu, Sun-Young Oh, Zhou Zhu, Buqu Hu, Robert J Homer, Lauren Cohn, Michael J Grusby, Jack A Elias, None, IL-13 Receptor α2 Selectively Inhibits IL-13-Induced Responses in the Murine Lung Journal of Immunology. ,vol. 180, pp. 522- 529 ,(2008) , 10.4049/JIMMUNOL.180.1.522
Garry M Walsh, Anti-IL-4/-13 based therapy in asthma Expert Opinion on Emerging Drugs. ,vol. 20, pp. 349- 352 ,(2015) , 10.1517/14728214.2015.1050377
Diego Maselli, Holly Keyt, Linda Rogers, Profile of lebrikizumab and its potential in the treatment of asthma. Journal of Asthma and Allergy. ,vol. 8, pp. 87- 92 ,(2015) , 10.2147/JAA.S69932
John W Steinke, Larry Borish, Th2 cytokines and asthma — Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists Respiratory Research. ,vol. 2, pp. 66- 70 ,(2001) , 10.1186/RR40
C. Blanchard, A. Mishra, H. Saito-Akei, P. Monk, I. Anderson, M. E. Rothenberg, Inhibition of human interleukin‐13‐induced respiratory and oesophageal inflammation by anti‐human‐interleukin‐13 antibody (CAT‐354) Clinical & Experimental Allergy. ,vol. 35, pp. 1096- 1103 ,(2005) , 10.1111/J.1365-2222.2005.02299.X
Chiba Yoshihiko, Goto Kumiko, Misawa Miwa, Interleukin-13-induced activation of signal transducer and activator of transcription 6 is mediated by an activation of Janus kinase 1 in cultured human bronchial smooth muscle cells Pharmacological Reports. ,vol. 64, pp. 454- 458 ,(2012) , 10.1016/S1734-1140(12)70788-0